How to Model Your Lab's 2027 Medicare Rate Exposure

Your lab ran the numbers for 2027 budgets this summer. Then CMS posted its preliminary Clinical Laboratory Fee Schedule rates on September 22, and those numbers stopped working.

If your test menu leans on high-volume Medicare work, the hit isn't theoretical. The American Hospital Association flagged cuts of up to 15% on almost 1,200 tests. And it called the commercial market data behind those cuts incomplete.

Here's what changed, how to figure out what it means for your lab specifically, and what to fix before January 1.

Why 15% Is Only the First Year

The 2027 rates come from the second full private payer reporting cycle under PAMA. CMS took the weighted median of what commercial payers paid for each test and set Medicare rates to match.

According to Becker's Hospital Review, CMS calculated preliminary medians for 1,528 codes. On average, those medians came in about 16% below 2026 Medicare rates. Genomic sequencing tests landed about 23% lower. Molecular pathology landed about 22% lower.

Here's the catch. Federal law caps any single test's cut at 15% per year in 2027, 2028 and 2029. So a test whose private payer median sits 30% below today's rate doesn't take the full hit at once. It takes 15% now and keeps sliding for two more years.

HFMA reports that 775 tests would take the maximum 15% cut in 2027 alone. If your top codes are on that list, you're not budgeting for one bad year. You're budgeting for three.

The Data Problem Behind Your Rate

Labs have pushed back hard on how these medians were built. The trade group ACLA told Healthcare Dive that the rates rely on data from just 2% of all labs paid under Medicare Part B in 2024.

The College of American Pathologists joined that call for reform. CAP's president said the current payment system isn't sustainable, as MedTech Dive reported. Some analysts expect Congress to delay the cuts again, as it has in prior years.

That's possible. But a delay isn't a plan. If you build your 2027 budget on a congressional rescue and it doesn't come, you've lost months you could've spent fixing leaks you control.

How to Model Your Own Exposure in an Afternoon

National averages won't tell you much. Your exposure depends on your test mix, your Medicare share and how much revenue you already lose before a claim is paid. The good news is you can size it quickly with data you already have.

Pull your last 12 months of Medicare paid claims by CPT code. Then run each code against the preliminary rate file. Labs that do this usually find most of the dollar risk sits in a short list of codes. Start there.

• Rank codes by Medicare dollars, not volume. A low-volume molecular panel can carry more exposure than your highest-volume chemistry test.
• Apply the preliminary rate to each top code. Multiply your 2025 or 2026 Medicare units by the new rate to see your projected 2027 revenue for that code.
• Flag codes facing the full 15% cut. These will likely keep falling in 2028 and 2029, so model all three years.
• Check your commercial contracts tied to Medicare. Some payer contracts pay a percentage of the Medicare fee schedule, so the cut can follow you there.
• Add your current denial and write-off rate. A cut on top of existing leakage compounds. Fixing the leak is the fastest way to offset the cut.

The Revenue You're Already Leaving Behind

Rate cuts get the headlines. Preventable denials do the quieter damage.

In a January 2026 MGMA Stat poll covered by Physicians Practice, 48% of respondents named denials and appeals as the biggest revenue leak in their cycle. Labs feel that more than most. You bill at high volume, often without face time with the patient, and you depend on ordering providers for diagnosis codes and documentation.

Every missing ABN, every diagnosis code that doesn't meet the LCD and every eligibility miss costs you the full test value. When reimbursement per test drops 15%, each of those misses matters even more. You have less margin to absorb them.

That's why lab billing needs rules built for labs. A general RCM tool won't validate LCD and NCD coverage at the line level or catch a missing ABN before the claim leaves. Our laboratory billing team builds those checks into the claim scrubber, and ADS clients run a nearly 99% first-pass clean claim rate across nearly 50 million EDI transactions a year.

What to Fix Before January 1

You can't change the fee schedule. You can change how much of it you actually collect. Use the next ten weeks to tighten the parts of your cycle that are fully in your control.

First, clean up front end data. Eligibility and demographic errors are the easiest denials to prevent. Second, audit your LCD coverage logic for your top 20 Medicare codes. Third, look hard at your molecular and genomic work. Those categories show the deepest gaps between Medicare and private payer rates.

Finally, make sure your EHR and billing workflow pass ordering provider documentation through cleanly. When diagnosis codes and medical necessity notes arrive incomplete, your team ends up chasing them after the fact. That's slow, and it's expensive.

For a broader view of the year ahead, read the Q4 issues every lab should be watching. Then see how revenue cycle management fits into a lab's 2027 plan.

Know Your Number Before CMS Finalizes Its Own

CMS expects to publish final 2027 rates in November, with an effective date of January 1. That gives you very little runway once the final file posts.

The labs that come through 2027 in the best shape won't be the ones that guessed right about Congress. They'll be the ones that knew their exposure early and closed their leaks while there was still time.

Want to see where your lab stands? Take the 2026 Lab Billing Compliance & Revenue Scorecard to benchmark your billing against the PAMA reset and find the gaps worth fixing first. Prefer to talk it through? Request a live demonstration or call 1-800-899-4237 ext. 2264. A real person answers in under 2 minutes.

Sources: AHA News (September 22, 2026); Becker's Hospital Review; HFMA; Healthcare Dive; MedTech Dive (College of American Pathologists); MGMA Stat via Physicians Practice.